Partnership with Dubai London Clinics & Hospitals
Oxford BioDynamics PLC
13 August 2026
13 August 2026
Oxford BioDynamics Plc
("OBD" or the "Company")
Oxford BioDynamics partners with Dubai London Clinics & Hospitals to bring EpiSwitch® PSE to the UAE
Oxford, UK - 13 August 2026 - Oxford BioDynamics Plc (AIM: OBD, the Company), the international biotechnology company advancing personalised healthcare through precision clinical diagnostic tests and EpiSwitch® Orion, its cloud-based 3D genomics platform for pharma and biotech partners, announces that it has entered into a partnership agreement with The Dubai London Clinics & Hospitals Group ("DLCH"), one of Dubai's longest-established private healthcare providers. This agreement makes OBD's EpiSwitch PSE prostate cancer test available across DLCH's network of clinics and hospitals across the United Arab Emirates.
Highlights
· Agreement to offer OBD's EpiSwitch PSE prostate cancer test across Dubai London Clinics & Hospitals network
· End-to-end clinical workflow successfully validated between Dubai and OBD's UK laboratory
· First commercial partnership for EpiSwitch PSE in the Gulf region
Under the agreement, patient blood samples will be collected at DLCH facilities and processed at OBD's laboratory in the UK. The end-to-end clinical workflow has been successfully validated between the two organisations.
The Company and DLCH will work together to support adoption across DLCH's clinician network, including local market development and engagement with regional payers. Test volumes are expected to build over time as these activities commence.
DLCH operates a network of five facilities, including the Australian Council on Healthcare Standard International (ACHS)-accredited Dubai London Hospital in Jumeirah, Dubai.
Further details on the partnership will be announced jointly by OBD and DLCH in due course.
Richard Compton, Chief Executive Officer at Oxford Biodynamics, said:
"We're delighted to be partnering with DLCH to make EpiSwitch PSE available across its facilities in the UAE. This is our first commercial partnership for the test in the Gulf region and an important milestone as we continue to expand internationally. We've already successfully validated the workflow between DLCH and our UK laboratory and look forward to working closely with the team to support adoption among clinicians and build awareness of the benefits our test can provide."
- ENDS -
For further information please contact:
|
Oxford BioDynamics Plc Iain Ross, Chairman Richard Compton, CEO Paul Stockdale, CFO |
+44 (0)1865 518910 |
|
Singer Capital Markets - Nominated Adviser and Broker Alex Bond / Russell Cook / Anastassiya Eley |
+44 (0)20 7496 3000 |
|
OAK Securities - Joint Broker Matthew Clarke / Tim Dainton / Calvin Man |
+44 (0)20 3973 3678 |
|
Camarco - Financial PR Marc Cohen / Sukaina Virji / Tilly Butcher / Fergus Young |
+44 (0)20 3757 4980 OBDFinancial@camarco.co.uk |
Notes for Editors
About Oxford BioDynamics plc
Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare through precision clinical diagnostic tests and EpiSwitch Orion, a cloud-based 3D genomics platform that transforms existing datasets into actionable insights for pharma and biotech partners.
Currently OBD has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CiRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.
The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch, which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.
EpiSwitch Orion is a cloud-based 3D genomics platform that enables pharmaceutical partners to transform standard sequencing data - including legacy whole genome datasets - into actionable discovery insights in hours rather than months. By revealing the genome's 3D architecture, EpiSwitch Orion illuminates the 90-95% of disease-associated variants in non-coding regions that traditional NGS and GWAS approaches cannot decipher, bridging the gap between statistical associations and druggable therapeutic targets. The platform is supported by the world's largest curated 3D genomics knowledgebase, featuring over 1.1 million anchor points and 15 million high-confidence genomic connections validated across 15,000+ patient samples in 50+ diseases - a foundation built over nearly two decades that enables partners to identify targets, build predictive classifier models, and design precision interventions at unprecedented speed.
OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.
The Company's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.
OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, www.oxfordbiodynamics.com, X (@OxBioDynamics) or LinkedIn.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.